ReviewJournal of analysis and testing2022
Improved Strategies for CRISPR-Cas12-based Nucleic Acids Detection.
Review in Journal of analysis and testing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Drivers of the paradigm shift in norovirus diagnostics: technological innovation, contextual demands, and collaborative synergy.Virology journal · 2026Review
- Towards deployable CRISPR-based nucleic acid detection.Progress in biomedical engineering (Bristol, England) · 2026Review
- CRISPR-Cas12a fluorescence assays identify weedy Amaranthus species.Scientific reports · 2026Article
- Catalytic Hairpin Assembly-Propelled Weak-Inputs-Strong-Outputs (CP-WISO) DNA Logic Nanodevices with Orthogonal Design and Contrary Logic Responses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A streamlined CRISPR-based test for tuberculosis detection directly from sputum.Science advances · 2025Article
- Ultrasensitive CRISPR/Cas12a-Based System for Detection ofCurrent issues in molecular biology · 2025Article
- CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential.Computational and structural biotechnology journal · 2025Review
- Advances in the application of CRISPR technology in pathogen detection: amplification-based and amplification-free strategies.Frontiers in cellular and infection microbiology · 2025Review
- Application of CRISPR-Cas System in Human Papillomavirus Detection Using Biosensor Devices and Point-of-Care Technologies.BME frontiers · 2025Review
- Development of a Copro-RPA-CRISPR/Cas12a assay to detect Echinococcus granulosus nucleic acids isolated from canine feces using NaOH-based DNA extraction method.PLoS neglected tropical diseases · 2024Article
- RPA-CRISPR/Cas12a assay for the diagnosis of bovine Anaplasma marginale infection.Scientific reports · 2024Article
- Review
- A CRISPR-Cas12a-based electrochemical biosensor for the detection of microphthalmia-associated transcription factor.Mikrochimica acta · 2024Article
- CRISPR/Cas12a-based method coupled with isothermal amplification to identifyFrontiers in microbiology · 2024Article
- A Critical Study on DNA Probes Attached to Microplate for CRISPR/Cas12 Trans-Cleavage Activity.Biosensors · 2023Article
- Point-of-Care Testing for Infectious Diseases Based on Class 2 CRISPR/Cas Technology.Diagnostics (Basel, Switzerland) · 2023Review
- CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- The applications of CRISPR/Cas-mediated genome editing in genetic hearing loss.Cell & bioscience · 2023Review
- Determination of adenosine by CRISPR-Cas12a system based on duplexed aptamer and molecular beacon reporter linked to gold nanoparticles.Mikrochimica acta · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has brought great challenges to traditional nucleic acid detection technology. Thus, it is urgent to develop a more simple and efficient nucleic acid detection technology. CRISPR-Cas12 has signal amplification ability, high sensitivity and high nucleic acid recognition specificity, so it is considered as a nucleic acid detection tool with broad development prospects and high application value. This review paper discusses recent advances in CRISPR-Cas12-based nucleic acid detection, with an emphasis on the new research methods and means to improve the nucleic acid detection capability of CRISPR-Cas12. Strategies for improving sensitivity, optimization of integrated detection, development of simplified detection mode and improvement of quantitative detection capabilities are included. Finally, the future development of CRISPR-Cas12-based nucleic acids detection is prospected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.